Clinical impact of Tirzepatide on patients with OSA and obesity
Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinsons disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
FCF peaked at over $29 billion in 2021 before plunging to $4.8 billion in 2023 due to the earnings collapse and working capital issues
One of the advantages Holst's group had in working on the issue was that researchers in Copenhagen were skilled at keeping pancreases alive that had been removed from pigs by perfusion with artificial blood
Rosenstock J., Ferrannini E